BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu Y, Swanson KM, Rojas RL, Wang Z, St Sauver JL, Visscher SL, Prokop LJ, Bielinski SJ, Wang L, Weinshilboum R, Borah BJ. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases. Genet Med 2020;22:475-86. [PMID: 31591509 DOI: 10.1038/s41436-019-0667-y] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Kamil AA, Lim KK, Koleva-kolarova R, Chowienczyk P, Wolfe CD, Fox-rushby J. Genetic-Guided Pharmacotherapy for Atrial Fibrillation: A Systematic and Critical Review of Economic Evaluations. Value in Health 2021. [DOI: 10.1016/j.jval.2021.09.013] [Reference Citation Analysis]
2 Magavern EF, Kaski JC, Turner RM, Janmohamed A, Borry P, Pirmohamed M. The Interface of Therapeutics and Genomics in Cardiovascular Medicine. Cardiovasc Drugs Ther 2021;35:663-76. [PMID: 33528719 DOI: 10.1007/s10557-021-07149-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Chatzopoulou F, Kyritsis KA, Papagiannopoulos CI, Galatou E, Mittas N, Theodoroula NF, Papazoglou AS, Karagiannidis E, Chatzidimitriou M, Papa A, Sianos G, Angelis L, Chatzidimitriou D, Vizirianakis IS. Dissecting miRNA–Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine. Cells 2022;11:607. [DOI: 10.3390/cells11040607] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. IJMS 2021;22:13302. [DOI: 10.3390/ijms222413302] [Reference Citation Analysis]
5 Beitelshees AL, Thomas CD, Empey PE, Stouffer GA, Angiolillo DJ, Franchi F, Tuteja S, Limdi NA, Lee JC, Duarte JD, Kreutz RP, Skaar TC, Coons JC, Giri J, Mcdonough CW, Rowland R, Stevenson JM, Thai T, Vesely MR, Wellen JT, Johnson JA, Winterstein AG, Cavallari LH, Lee CR; Implementing Genomics in Practice (IGNITE) Network Pharmacogenetics Working Group. CYP2C19 Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings. JAHA. [DOI: 10.1161/jaha.121.024159] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zubiaur P, Mejía-Abril G, Navares-Gómez M, Villapalos-García G, Soria-Chacartegui P, Saiz-Rodríguez M, Ochoa D, Abad-Santos F. PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics. J Clin Med 2021;10:3772. [PMID: 34501219 DOI: 10.3390/jcm10173772] [Reference Citation Analysis]
7 Ragia G, Manolopoulos VG. Pharmacogenomics of anticoagulation therapy: the last 10 years. Pharmacogenomics 2019;20:1113-7. [DOI: 10.2217/pgs-2019-0149] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Brunette CA, Dong OM, Vassy JL, Danowski ME, Alexander N, Antwi AA, Christensen KD. A Cost-Consequence Analysis of Preemptive SLCO1B1 Testing for Statin Myopathy Risk Compared to Usual Care. J Pers Med 2021;11:1123. [PMID: 34834475 DOI: 10.3390/jpm11111123] [Reference Citation Analysis]
9 Sang S, Guo X, Wang J, Li H, Ma X. Real-time and label-free detection of VKORC1 genes based on a magnetoelastic biosensor for warfarin therapy. J Mater Chem B 2020;8:6271-6. [PMID: 32426797 DOI: 10.1039/d0tb00354a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Guy JW, Patel I, Oestreich JH. Clinical Application and Educational Training for Pharmacogenomics. Pharmacy (Basel) 2020;8:E163. [PMID: 32899212 DOI: 10.3390/pharmacy8030163] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Swanson KM, Zhu Y, Rojas RL, St Sauver JL, Bielinski SJ, Jacobsen DJ, Visscher SL, Wang L, Weinshilboum R, Borah BJ. Comparing outcomes and costs among warfarin-sensitive patients versus warfarin-insensitive patients using The Right Drug, Right Dose, Right Time: Using genomic data to individualize treatment (RIGHT) 10K warfarin cohort. PLoS One 2020;15:e0233316. [PMID: 32428022 DOI: 10.1371/journal.pone.0233316] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Westergaard N, Tarnow L, Vermehren C. Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy. Metabolites 2021;11:96. [PMID: 33578832 DOI: 10.3390/metabo11020096] [Reference Citation Analysis]
13 B Tata E, A Ambele M, S Pepper M. Barriers to Implementing Clinical Pharmacogenetics Testing in Sub-Saharan Africa. A Critical Review. Pharmaceutics 2020;12:E809. [PMID: 32858798 DOI: 10.3390/pharmaceutics12090809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Zhu Y, Moriarty JP, Swanson KM, Takahashi PY, Bielinski SJ, Weinshilboum R, Wang L, Borah BJ. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none? Genet Med 2021;23:461-70. [PMID: 33041335 DOI: 10.1038/s41436-020-00995-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Carrascal-Laso L, Franco-Martín MÁ, Marcos-Vadillo E, Ramos-Gallego I, García-Berrocal B, Mayor-Toranzo E, Sánchez-Iglesias S, Lorenzo C, Sevillano-Jiménez A, Sánchez-Martín A, García-Salgado MJ, Isidoro-García M. Economic Impact of the Application of a Precision Medicine Model (5SPM) on Psychotic Patients. Pharmgenomics Pers Med 2021;14:1015-25. [PMID: 34429634 DOI: 10.2147/PGPM.S320816] [Reference Citation Analysis]
16 Karamperis K, Koromina M, Papantoniou P, Skokou M, Kanellakis F, Mitropoulos K, Vozikis A, Müller DJ, Patrinos GP, Mitropoulou C. Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J 2021;21:533-41. [PMID: 34215853 DOI: 10.1038/s41397-021-00249-1] [Reference Citation Analysis]
17 Huebner T, Steffens M, Linder R, Fracowiak J, Langner D, Garling M, Falkenberg F, Roethlein C, Gomm W, Haenisch B, Stingl J. Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR. BMJ Open 2020;10:e032624. [PMID: 32345696 DOI: 10.1136/bmjopen-2019-032624] [Reference Citation Analysis]
18 Hiratsuka M, Zhou Y, Lauschke VM. Editorial: Population Pharmacogenomics (PGx): From Variant Identification to Clinical Implementation. Front Genet 2021;12:736626. [PMID: 34422026 DOI: 10.3389/fgene.2021.736626] [Reference Citation Analysis]
19 Bienfait K, Chhibber A, Marshall JC, Armstrong M, Cox C, Shaw PM, Paulding C. Current challenges and opportunities for pharmacogenomics: perspective of the Industry Pharmacogenomics Working Group (I-PWG). Hum Genet 2021. [PMID: 34081195 DOI: 10.1007/s00439-021-02282-3] [Reference Citation Analysis]
20 Zammarchi G, Del Zompo M, Squassina A, Pisanu C. Increasing engagement in pharmacology and pharmacogenetics education using games and online resources: The PharmacoloGenius mobile app. Drug Dev Res 2020. [PMID: 32633017 DOI: 10.1002/ddr.21714] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 de Lara DV, de Melo DO, Araújo Silva LC, Gonçalves TS, Júnior Lima Santos PC. Pharmacogenetics of clopidogrel and warfarin in the treatment of cardiovascular diseases: an overview of reviews. Pharmacogenomics 2022. [PMID: 35380455 DOI: 10.2217/pgs-2021-0158] [Reference Citation Analysis]
22 Mugosa S, Todorovic Z, Cukic J, Sahman-Zaimovic M, Djordjevic N. ABCB1 polymorphism in clopidogrel-treated Montenegrin patients. Open Life Sci 2021;16:142-9. [PMID: 33817306 DOI: 10.1515/biol-2021-0017] [Reference Citation Analysis]
23 Westergaard N, Tarnow L, Vermehren C. Comparison of Multidrug Use in the General Population and among Persons with Diabetes in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines. Pharmaceuticals (Basel) 2021;14:899. [PMID: 34577599 DOI: 10.3390/ph14090899] [Reference Citation Analysis]
24 Lara DV, Melo DO, Silva RAM, Santos PCJL. Pharmacogenetic testing in psychiatry and neurology: an overview of reviews. Pharmacogenomics 2021;22:505-13. [PMID: 33973477 DOI: 10.2217/pgs-2020-0187] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Lim KK, Koleva-Kolarova R, Chowienczyk P, Wolfe CDA, Fox-Rushby J. Genetic-guided pharmacotherapy for venous thromboembolism: a systematic and critical review of economic evaluations. Pharmacogenomics J 2021. [PMID: 34131314 DOI: 10.1038/s41397-021-00243-7] [Reference Citation Analysis]
26 Pandi MT, Koromina M, Vonitsanos G, van der Spek PJ, Patrinos GP, Mitropoulou C. Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data. Pharmacol Res 2022;:106187. [PMID: 35331864 DOI: 10.1016/j.phrs.2022.106187] [Reference Citation Analysis]
27 Ikonnikova AY, Filippova MA, Surzhikov SA, Pozhitnova VO, Kazakov RE, Lisitsa TS, Belkov SA, Nasedkina TV. Biochip-based approach for comprehensive pharmacogenetic testing. Drug Metab Pers Ther 2020. [PMID: 33780199 DOI: 10.1515/dmpt-2020-0155] [Reference Citation Analysis]
28 Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. The Role of Pharmacogenomics in Contemporary Cardiovascular Therapy: A position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J Cardiovasc Pharmacother 2021:pvab018. [PMID: 33638977 DOI: 10.1093/ehjcvp/pvab018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wang X, Tang B, Zhou M, Liu L, Feng X, Wang X, Qiu K. Efficacy and safety of genotype-guided warfarin dosing versus non-genotype-guided warfarin dosing strategies: A systematic review and meta-analysis of 27 randomized controlled trials. Thromb Res 2021;210:42-52. [PMID: 34999431 DOI: 10.1016/j.thromres.2021.12.023] [Reference Citation Analysis]
30 Micaglio E, Locati ET, Monasky MM, Romani F, Heilbron F, Pappone C. Role of Pharmacogenetics in Adverse Drug Reactions: An Update towards Personalized Medicine. Front Pharmacol 2021;12:651720. [PMID: 33995067 DOI: 10.3389/fphar.2021.651720] [Reference Citation Analysis]